NasdaqGM - Delayed Quote • USD
Vera Therapeutics, Inc. (VERA)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 7:08 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 7 | 7 |
| Avg. Estimate | -0.53 | -0.53 | -2.16 | -2.33 |
| Low Estimate | -0.6 | -0.65 | -2.62 | -3.17 |
| High Estimate | -0.46 | -0.47 | -1.98 | -1.85 |
| Year Ago EPS | -0.8 | -0.46 | -2.25 | -2.16 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 7 | 7 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.6 | -0.69 | -0.53 | -0.51 |
| EPS Actual | -0.8 | -0.46 | -0.45 | -0.6 |
| Difference | -0.2 | 0.23 | 0.08 | -0.09 |
| Surprise % | -33.30% | 33.30% | 15.10% | -17.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.53 | -0.53 | -2.16 | -2.33 |
| 7 Days Ago | -0.53 | -0.53 | -2.16 | -2.33 |
| 30 Days Ago | -0.52 | -0.52 | -2.17 | -2.16 |
| 60 Days Ago | -0.52 | -0.55 | -2.19 | -2.05 |
| 90 Days Ago | -0.52 | -0.55 | -2.16 | -2.05 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | VERA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 33.80% | -- | -- | 1.50% |
| Next Qtr. | -15.20% | -- | -- | 11.40% |
| Current Year | 4.00% | -- | -- | 5.20% |
| Next Year | -7.90% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Guggenheim: Buy to Buy | 4/5/2024 |
| Maintains | Guggenheim: Buy to Buy | 3/27/2024 |
| Maintains | Wedbush: Neutral to Neutral | 3/21/2024 |
| Maintains | Wedbush: Neutral to Neutral | 1/26/2024 |
| Upgrade | Raymond James: Outperform to Strong Buy | 1/26/2024 |
| Initiated | Oppenheimer: Outperform | 1/25/2024 |
Related Tickers
ALPN Alpine Immune Sciences, Inc.
64.57
+0.03%
JANX Janux Therapeutics, Inc.
48.21
-3.15%
BHVN Biohaven Ltd.
38.72
-2.25%
APGE Apogee Therapeutics, Inc.
46.54
-6.49%
CYTK Cytokinetics, Incorporated
66.82
+1.91%
DYN Dyne Therapeutics, Inc.
24.98
-1.81%
RNA Avidity Biosciences, Inc.
25.09
-0.20%
IDYA IDEAYA Biosciences, Inc.
39.85
+2.13%
MLTX MoonLake Immunotherapeutics
42.43
-1.90%
RARE Ultragenyx Pharmaceutical Inc.
44.28
-1.84%